StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for SUPN yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $50.88 | $49.43 | -2.85% | 0.6M |
| 05-18 | $49.34 | $48.33 | -2.05% | 0.6M |
| 05-19 | $48.38 | $47.62 | -1.57% | 0.6M |
| 05-20 | $48.27 | $48.69 | +0.87% | 0.6M |
| 05-21 | $48.68 | $49.38 | +1.44% | 0.5M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $207.71M | $718.95M | $507.38M | $315.28M |
Operating Income | $-8.33M | $-62.28M | $-58.35M | $1.89M |
Net Income | $-2.29M | $-38.55M | $-34.45M | $22.50M |
EPS (Diluted) | $-0.04 | $-0.68 | $-0.61 | $0.19 |
Total Assets | $1.50B | $1.45B | $1.42B | $1.38B |
Total Liabilities | $423.92M | $390.93M | $370.09M | $318.50M |
Cash & Equivalents | $184.87M | $128.45M | $151.37M | $144.71M |
Free Cash Flow OCF − CapEx | $66.52M | $45.99M | $26.56M | $88.35M |
Shares Outstanding | 58.04M | 57.46M | 57.12M | 56.12M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.